OBJECTIVE: To examine associations between tau and amyloid β (Aβ) molecular positron emission tomography (PET) and both Alzheimer-related pathology and 4-repeat tau pathology in autopsy-confirmed frontotemporal lobar degeneration (FTLD). METHODS: Twenty-four patients had [18 F]-flortaucipir-PET and died with FTLD (progressive supranuclear palsy [PSP], n = 10; corticobasal degeneration [CBD], n = 10; FTLD-TDP, n = 3; and Pick disease, n = 1). All but 1 had Pittsburgh compound B (PiB)-PET. Braak staging, Aβ plaque and neurofibrillary tangle counts, and semiquantitative tau lesion scores were performed. Flortaucipir standard uptake value ratios (SUVRs) were calculated in a temporal meta region of interest (meta-ROI), entorhinal cortex and cortical/subcortical regions selected to match the tau lesion analysis. Global PiB SUVR was calculated. Autoradiography was performed in 1 PSP patient, with digital pathology used to quantify tau burden. RESULTS: Nine cases (37.5%) had Aβ plaques. Global PiB SUVR correlated with Aβ plaque count, with 100% specificity and 50% sensitivity for diffuse plaques. Twenty-one (87.5%) had Braak stages I to IV. Flortaucipir correlated with neurofibrillary tangle counts in entorhinal cortex, but entorhinal and meta-ROI SUVRs were not elevated in Braak IV or primary age-related tauopathy. Flortaucipir uptake patterns differed across FTLD pathologies and could separate PSP and CBD. Flortaucipir correlated with tau lesion score in red nucleus and midbrain tegmentum across patients, but not in cortical or basal ganglia regions. Autoradiography demonstrated minimal uptake of flortaucipir, although flortaucipir correlated with quantitative tau burden across regions. INTERPRETATION: Molecular PET shows expected correlations with Alzheimer-related pathology but lacks sensitivity to detect mild Alzheimer pathology in FTLD. Regional flortaucipir uptake was able to separate CBD and PSP. ANN NEUROL 2020;88:1009-1022.
OBJECTIVE: To examine associations between tau and amyloid β (Aβ) molecular positron emission tomography (PET) and both Alzheimer-related pathology and 4-repeat tau pathology in autopsy-confirmed frontotemporal lobar degeneration (FTLD). METHODS: Twenty-four patients had [18 F]-flortaucipir-PET and died with FTLD (progressive supranuclear palsy [PSP], n = 10; corticobasal degeneration [CBD], n = 10; FTLD-TDP, n = 3; and Pick disease, n = 1). All but 1 had Pittsburgh compound B (PiB)-PET. Braak staging, Aβ plaque and neurofibrillary tangle counts, and semiquantitative tau lesion scores were performed. Flortaucipir standard uptake value ratios (SUVRs) were calculated in a temporal meta region of interest (meta-ROI), entorhinal cortex and cortical/subcortical regions selected to match the tau lesion analysis. Global PiB SUVR was calculated. Autoradiography was performed in 1 PSPpatient, with digital pathology used to quantify tau burden. RESULTS: Nine cases (37.5%) had Aβ plaques. Global PiB SUVR correlated with Aβ plaque count, with 100% specificity and 50% sensitivity for diffuse plaques. Twenty-one (87.5%) had Braak stages I to IV. Flortaucipir correlated with neurofibrillary tangle counts in entorhinal cortex, but entorhinal and meta-ROI SUVRs were not elevated in Braak IV or primary age-related tauopathy. Flortaucipir uptake patterns differed across FTLD pathologies and could separate PSP and CBD. Flortaucipir correlated with tau lesion score in red nucleus and midbrain tegmentum across patients, but not in cortical or basal ganglia regions. Autoradiography demonstrated minimal uptake of flortaucipir, although flortaucipir correlated with quantitative tau burden across regions. INTERPRETATION: Molecular PET shows expected correlations with Alzheimer-related pathology but lacks sensitivity to detect mild Alzheimer pathology in FTLD. Regional flortaucipir uptake was able to separate CBD and PSP. ANN NEUROL 2020;88:1009-1022.
Authors: F Ali; J L Whitwell; P R Martin; M L Senjem; D S Knopman; C R Jack; V J Lowe; R C Petersen; B F Boeve; K A Josephs Journal: J Neurol Date: 2018-03-01 Impact factor: 4.849
Authors: J L Whitwell; C R Jack; J E Parisi; M L Senjem; D S Knopman; B F Boeve; R Rademakers; M Baker; R C Petersen; D W Dickson; K A Josephs Journal: Neurology Date: 2010-12-14 Impact factor: 9.910
Authors: Jennifer L Whitwell; Peter R Martin; Joseph R Duffy; Heather M Clark; Mary M Machulda; Christopher G Schwarz; Stephen D Weigand; Irene Sintini; Matthew L Senjem; Nilufer Ertekin-Taner; Hugo Botha; Rene L Utianski; Jonathan Graff-Radford; David T Jones; Bradley F Boeve; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs Journal: Neurology Date: 2019-01-11 Impact factor: 9.910
Authors: Ira Driscoll; Juan C Troncoso; Gay Rudow; Jitka Sojkova; Olga Pletnikova; Yun Zhou; Michael A Kraut; Luigi Ferrucci; Chester A Mathis; William E Klunk; Richard J O'Brien; Christos Davatzikos; Dean F Wong; Susan M Resnick Journal: Acta Neuropathol Date: 2012-08-05 Impact factor: 17.088
Authors: John L Robinson; Ning Yan; Carrie Caswell; Sharon X Xie; EunRan Suh; Vivianna M Van Deerlin; Garrett Gibbons; David J Irwin; Murray Grossman; Edward B Lee; Virginia M-Y Lee; Bruce Miller; John Q Trojanowski Journal: J Neuropathol Exp Neurol Date: 2020-03-01 Impact factor: 3.685
Authors: Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad Journal: Alzheimers Dement Date: 2016-02-15 Impact factor: 21.566
Authors: Luca Passamonti; Patricia Vázquez Rodríguez; Young T Hong; Kieren S J Allinson; David Williamson; Robin J Borchert; Saber Sami; Thomas E Cope; W Richard Bevan-Jones; P Simon Jones; Robert Arnold; Ajenthan Surendranathan; Elijah Mak; Li Su; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe Journal: Brain Date: 2017-03-01 Impact factor: 13.501
Authors: Clifford R Jack; Heather J Wiste; Hugo Botha; Stephen D Weigand; Terry M Therneau; David S Knopman; Jonathan Graff-Radford; David T Jones; Tanis J Ferman; Bradley F Boeve; Kejal Kantarci; Val J Lowe; Prashanthi Vemuri; Michelle M Mielke; Julie A Fields; Mary M Machulda; Christopher G Schwarz; Matthew L Senjem; Jeffrey L Gunter; Ronald C Petersen Journal: Brain Date: 2019-10-01 Impact factor: 13.501
Authors: Fatma Ozlem Hokelekli; Joseph R Duffy; Heather M Clark; Rene L Utianski; Hugo Botha; Farwa Ali; Julie A Stierwalt; Mary M Machulda; R Ross Reichard; Dennis W Dickson; Jennifer L Whitwell; Keith A Josephs Journal: Mov Disord Date: 2021-10-10 Impact factor: 10.338
Authors: Keith A Josephs; Nirubol Tosakulwong; Stephen D Weigand; Marina Buciuc; Val J Lowe; Dennis W Dickson; Jennifer L Whitwell Journal: J Nucl Med Date: 2021-09-23 Impact factor: 11.082
Authors: Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger Journal: Nat Rev Neurol Date: 2021-08-23 Impact factor: 42.937
Authors: Maura Malpetti; Sanne S Kaalund; Kamen A Tsvetanov; Timothy Rittman; Mayen Briggs; Kieren S J Allinson; Luca Passamonti; Negin Holland; P Simon Jones; Tim D Fryer; Young T Hong; Antonina Kouli; W Richard Bevan-Jones; Elijah Mak; George Savulich; Maria Grazia Spillantini; Franklin I Aigbirhio; Caroline H Williams-Gray; John T O'Brien; James B Rowe Journal: J Nucl Med Date: 2021-11-18 Impact factor: 11.082
Authors: Adam Martersteck; Ivan Ayala; Daniel T Ohm; Callen Spencer; Christina Coventry; Sandra Weintraub; Eileen H Bigio; M -Marsel Mesulam; Changiz Geula; Emily Rogalski Journal: Acta Neuropathol Commun Date: 2022-08-09 Impact factor: 7.578
Authors: Jennifer L Whitwell; Nirubol Tosakulwong; Christopher C Schwarz; Matthew L Senjem; Anthony J Spychalla; Joseph R Duffy; Jon Graff-Radford; Mary M Machulda; Bradley F Boeve; David S Knopman; Ronald C Petersen; Val J Lowe; Clifford R Jack; Dennis W Dickson; Joseph E Parisi; Keith A Josephs Journal: Neurology Date: 2020-09-28 Impact factor: 9.910